Familial prostate cancer and HOXB13 founder mutations: geographic and racial/ethnic variations

2012 ◽  
Vol 132 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Henry T. Lynch ◽  
Trudy G. Shaw
Keyword(s):  
Prostate Cancer ◽  
Founder Mutations ◽  
Ethnic Variations ◽  
Racial Ethnic

Racial/ethnic disparities in patient experiences with care and Gleason score at diagnosis of prostate cancer: a SEER-CAHPS study

2022 ◽  
Author(s):  
Stephanie Navarro ◽  
Xiaohui Hu ◽  
Aaron Mejia ◽  
Carol Y. Ochoa ◽  
Trevor A. Pickering ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gleason Score ◽  
Ethnic Disparities ◽  
Patient Experiences ◽  
Racial Ethnic

scholarly journals Geographic and Racial/Ethnic Variations in Patterns of Multimorbidity Burden in Patients with Type 2 Diabetes

2014 ◽  
Vol 30 (1) ◽  
pp. 25-32 ◽  
Author(s):  
Cheryl P. Lynch ◽  
Mulugeta Gebregziabher ◽  
R. Neal Axon ◽  
Kelly E. Hunt ◽  
Elizabeth Payne ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Ethnic Variations ◽  
Racial Ethnic

Genomic landscape of advanced prostate cancer in racial minority populations: Real-world experience in a safety-net hospital oncology clinic.

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 14-14
Author(s):  
Tamer Khashab ◽  
Alexander D Le ◽  
Samantha Cohen ◽  
Salma Kaochar ◽  
Heidi Dowst ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Real World ◽  
Safety Net ◽  
Access To Healthcare ◽  
Minority Populations ◽  
Precision Oncology ◽  
Genomic Landscape ◽  
Safety Net Hospital ◽  
Ngs Data ◽  
Racial Ethnic

14 Background: The largest US cancer health disparity exists in prostate cancer (PC), with African American (AA) men having: ~1.6-1.8-fold higher risk of developing PC; younger age and more advanced stage at diagnosis; increased risk of recurrence after radical prostatectomy; and up to 2.5-fold higher mortality rate relative to men of other ancestries. Access to healthcare and other socioeconomic and environmental factors contribute to the disparity in clinical outcomes. However, genetic factors may also be involved, and their role and prevalence need to be better defined, especially in real-world clinical settings, as the high cost of next-generation sequencing (NGS) may have resulted in underrepresentation of uninsured and minority patients in prior studies. Methods: We retrospectively analyzed NGS data obtained via Tempus|xT tissue assay (DNA sequencing of 648 genes in tumor and matched normal samples at 500x depth) and/or Tempus|xF liquid biopsy assay (ctDNA sequencing of 105 genes in peripheral blood samples at 5,000x depth) for germline and/or somatic mutations detected in 100 patients (53 AA) receiving androgen deprivation therapy for locally advanced, biochemically recurrent or metastatic PC at Ben Taub Hospital (BTH), a safety net hospital in Harris County/Houston serving a patient population of which 91% are racial/ethnic minorities. For confirmation, we analyzed de-identified NGS data from a nationwide cohort of 1,211 metastatic PC patients (213 AA) previously sequenced with xT and/or xF by Tempus Labs (Chicago, IL). Results: We found higher frequencies of AR (18.9%), TP53 (41.5%), SPOP (20.7%) and homologous recombination repair (HRR) pathway gene mutations, in particular BRCA2 (17%), in our AA BTH cohort, as compared to PC patients of other races/ethnicities. The latter finding was confirmed in the nationwide Tempus Labs cohort, with 91/213 (42.7%) AA patients exhibiting mutation in at least one of 14 HRR pathway genes associated with PC sensitivity to PARP inhibitors, compared to 347/998 (34.7%) non-AA patients (P < 0.05). This difference was mainly driven by higher frequency of BRCA2 (16.9%), CDK12 (8%) and PALB2 (5.2%) mutations in AA patients. In both cohorts, TMPRSS2 fusions were much less common in AA PC patients. Conclusions: The observed high frequency of mutations in key PC drivers in AA patients may reflect differences in disease biology between racial/ethnic groups or the more advanced disease presentation of AA patients due to socioeconomic factors delaying access to healthcare. Our study provides a real-world snapshot of the genomic landscape of advanced PC in a safety net hospital serving large racial/ethnic minority populations and highlights the role that NGS testing can play to improve their access to treatment with novel targeted therapies and to biomarker-based Precision Oncology clinical trials.

RACIAL/ETHNIC DISPARITIES IN THE TREATMENT OF LOCALIZED/REGIONAL PROSTATE CANCER

2004 ◽  
Vol 171 (4) ◽  
pp. 1504-1507 ◽  
Author(s):  
WILLIE UNDERWOOD ◽  
SONYA DeMONNER ◽  
PETER UBEL ◽  
ANGELA FAGERLIN ◽  
MARTIN G. SANDA ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Ethnic Disparities ◽  
Racial Ethnic

scholarly journals Racial/ethnic disparities in de novo metastases sites and survival outcomes for patients with primary breast, colorectal, and prostate cancer

2018 ◽  
Vol 7 (4) ◽  
pp. 1183-1193 ◽  
Author(s):  
Tomi Akinyemiju ◽  
Swati Sakhuja ◽  
John Waterbor ◽  
Maria Pisu ◽  
Sean F. Altekruse
Keyword(s):  
Prostate Cancer ◽  
De Novo ◽  
Ethnic Disparities ◽  
Survival Outcomes ◽  
Racial Ethnic

scholarly journals 0863 Age-categorized Trends In Self-reported Sleep Duration For The Non-institutionalized U.s. Civilian Population From 2004-2013: Considerations Of Racial/ethnic Variations

SLEEP ◽  
2020 ◽  
Vol 43 (Supplement_1) ◽  
pp. A329-A329
Author(s):  
M Christina ◽  
O M Bubu ◽  
T Donley ◽  
J Blanc ◽  
E Oji ◽  
...  
Keyword(s):  
Sleep Duration ◽  
Multinomial Logistic Regression ◽  
Population Level ◽  
Racial Categories ◽  
Logistic Regression Models ◽  
Short Sleep ◽  
Using Data ◽  
Study Participants ◽  
Ethnic Variations ◽  
Racial Ethnic

Abstract Introduction We examined age-categorized trends in self-reported sleep duration using data from the National Health Interview Survey (NHIS) 2004-2013 and explored how these trends may vary based on individuals’ race/ethnicity. Methods Study participants were aged 18-85 (N=258,158). Sleep duration within a 24-hour period on average was categorized as ≤ 6hrs (short-sleep), 7-8 hours (adequate-sleep), and ≥ 9hrs (long-sleep). Age was categorized as 18 - &lt;26, 26 - &lt;65 and 65 - 85. Racial categories included non-Hispanic Whites (NHW), Blacks/African Americans (AAs) and Hispanics. Adjusted multinomial logistic regression models examined trends in self-reported sleep duration across age-categories and assessed race/ethnic differences in these trends. Results Mean sleep duration (hrs.) across all years was 7.4, 7.0, and 7.5, for ages 18 - &lt;26, 26 - &lt;65 and 65 - 85, respectively and was relatively stable from 2004-2013. However, compared to individuals ages 18 - &lt;26, those categorized as ages 26 - &lt;65 were 55% more likely to be short sleepers while those ages 65 - 85 were 20% less likely to be short sleepers (P &lt; .001 for all). Mean sleep duration was 7.2hrs, for NHW and 7.1hrs for AAs and Hispanics, and showed increasing trend toward short sleep beginning in 2007 through 2013 (P &lt;.01 for trend). In the age 18 - &lt;26 category, compared to whites, blacks and Hispanics were 35% and 29% more likely to be short sleepers, respectively. In the age 26 - &lt;65 category, compared to whites, blacks and Hispanics were 35% and 21% more likely to be short sleepers, respectively. In the age 65 - 85 category, compared to whites, blacks were 19% more likely to be short sleepers (P &lt; .001 for all). Conclusion Continued surveillance of population-level sleep trends among minority populations is essential as growing race/ethnic (age specific) disparities in self-reported sleep duration may have consequences for racial/ethnic health disparities. Support NIH/NIA/NHLBI (L30-AG064670, CIRAD P30AG059303 Pilot, T32HL129953, R01AG056531, R25HL105444, R25NS094093, K07AG05268503, R01HL142066, K23HL125939)

Sign in / Sign up

Export Citation Format

Share Document